Enantioselective Synthesis of 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) via Enzymatic Desymmetrization

Mark McLaughlin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Williams(Hospital of the University of Pennsylvania), Billy Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey C. Moore(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Murray(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Lieberman(Oregon Health & Science University), Feng Peng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew Gibson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Zhiguo J. Song(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen P. Keen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Erika M. Milczek(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Reamer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lin Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ji Qi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lushi Tan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jongrock Kong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kevin M. Belyk(Merck & Co., Inc., Rahway, NJ, USA (United States))
Organic Letters
February 6, 2017
Cited by 69


Related Papers